CI

At a glance

ClinicalIndex Comparison Record
Phase 2Withdrawn· 0 enrolled
Drug / intervention
Anlotinib +3 moredrug
Likely dose
Anlotinib 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05481775
NCT05481775Phase 2Withdrawn
Withdrawn
CompareCT.gov

Evaluating Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy Versus Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective, Randomized Controlled Phase II Clinical Trial

Sun Yat-sen University·interventional·Posted Aug 1, 2022·Updated Nov 21, 2022

In Brief

A Phase 2 clinical trial evaluating Anlotinib, Chemotherapy, and 2 other interventions for Locally Advanced Non-small Cell Lung Cancer and Efficacy and Safety. Withdrawn before enrollment, across 1 site.

Signals

Trial was withdrawn before enrollment

Detailed Summary

This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Non-small Cell Lung Cancer, Efficacy and Safety
CountriesChina
Collaborators--

Timeline

Phase 2WithdrawnFinished
2023202420252026
First PostedAug 1, 2022
Enrollment StartApr 1, 2022
Primary CompletionApr 1, 2025
Study CompletionSep 30, 2025
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 3.9 years ago

Interventions

Anlotinibdrug

Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.

Chemotherapydrug

Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW

Radiotherapyradiation

Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.

Immunotherapydrug

consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)